Navigation Links
Neurobiological Technologies Sets Date for Research and Development Day
Date:2/14/2008

EMERYVILLE, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced the date of its first annual Research & Development Day to be held on Tuesday, March 4, 2008. The event will take place from 8:00 to 9:30 a.m. at the Mandarin Oriental Hotel, 80 Columbus Circle, 36th Floor, South Salon, in New York City.

The focus of the meeting will be Viprinex(TM) (ancrod), NTI's compound for the treatment of acute ischemic stroke, currently in two Phase 3 clinical trials.

Questions about the R&D Development Day can be directed to Walter Kass, NTI Investor Counsel, 212-300-4708.

About Neurobiological Technologies, Inc.

NTI is a biopharmaceutical company focused on developing novel agents for central nervous system conditions. The Company's most advanced product candidate is Viprinex (ancrod), a novel multi-targeted agent currently undergoing pivotal Phase 3 clinical testing for the potential treatment of acute ischemic stroke.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
2. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
3. Neurobiological Technologies Sets Date for Second Quarter Financial Results
4. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
7. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
8. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
9. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
10. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
11. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... One Million Solutions ... (SafeTEC™), $3 million in investment towards 15+ TEC Validation Projects™. As a pre-competitive ... their applicability in drug safety assessment, for the industry as a whole. , ...
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today ... will allow more customers to receive their primers in ... or compromise in quality found with other providers. Express ... United States at no additional fee. ... routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
Breaking Biology Technology:
(Date:1/12/2017)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer ... it has signed agreements with seven strategic partners across ... Middle East for commercialization of the Trovera™ ... of international distribution agreements for Trovagene,s CLIA based liquid ... The initial partners will introduce Trovagene,s liquid biopsy tests ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/3/2017)... Onitor, provider of digital health technology for ... innovative biometric data-driven program designed to aid weight loss ... 2017 Consumer Electronics Show (CES) in Las ... the World Health Organization (WHO), have identified lifestyle risks ... are overweight or obese. WHO also states that more ...
Breaking Biology News(10 mins):